SPHK2 and nonpapillary renal cell carcinoma: Thus, we proposed that NEDD4L can inhibit Akt activation in ccRCC possibly through degrading its upstream activators such as STK35, SphK2, CTR1, and PIK3CA, which were previously reported in different cancers [25–27, 29].